Studies on the Role of Vitronectin and Plasminogen-Activator Inhibitor-1 Complexes Beyond Inhibiting Proteases: Binding to the Extracellular Matrix, Cell Interactions and Pathogenesis

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Mutative expression in Candida albicans infection and cytokine signaling network in gene knockout mice

  2010cited by this paper
• Interactions of plasminogen activator inhibitor-1 with vitronectin involve an extensive binding surface and induce mutual conformational rearrangements.

  2009influential reference
• Will integrin inhibitors have proangiogenic effects in the clinic?

  2009cited by this paper
• Clustering of α5β1 integrins determines adhesion strength whereas αvβ3 and talin enable mechanotransduction

  2009cited by this paper
• Integrin-linked kinase is required for vitronectin-mediated internalization of Streptococcus pneumoniae by host cells

  2009cited by this paper
• Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes

  2008cited by this paper
• Collagen receptor integrins: rising to the challenge.

  2008cited by this paper
• Cilengitide: an integrin-targeting arginine–glycine–aspartic acid peptide with promising activity for glioblastoma multiforme

  2008cited by this paper
• Collagens at a glance

  2007cited by this paper
• Small Molecule Inhibitors of Integrin α2β1

  2007cited by this paper
• Changes in glycosylation of vitronectin modulate multimerization and collagen binding during liver regeneration.

  2007cited by this paper
• Structure-function relationships of plasminogen activator inhibitor-1 and its potential as a therapeutic agent.

  2007cited by this paper
• Defining the Native Disulfide Topology in the Somatomedin B Domain of Human Vitronectin*

  2007cited by this paper
• Small molecule inhibitors of integrin alpha2beta1.

  2007cited by this paper
• Solution structure of recombinant somatomedin B domain from vitronectin produced in Pichia pastoris

  2007cited by this paper
• Host-pathogen interactions and the pathological consequences of acute systemic Candida albicans infections in mice.

  2006influential reference
• Integrin ligands at a glance

  2006cited by this paper
• Structure of Human Urokinase Plasminogen Activator in Complex with Its Receptor

  2006cited by this paper
• Studying multiprotein complexes by multisignal sedimentation velocity analytical ultracentrifugation.

  2005influential reference
• Central Obesity, the Metabolic Syndrome, and Plasminogen Activator Inhibitor‐1 in Young Adults

  2005cited by this paper
• Vitronectin stabilizes thrombi and vessel occlusion but plays a dual role in platelet aggregation

  2005cited by this paper
• Mice with disseminated candidiasis die of progressive sepsis.

  2005cited by this paper
• Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide

  2005cited by this paper
• A model for the three-dimensional structure of human plasma vitronectin from small-angle scattering measurements.

  2005influential reference
• Trends in immunotherapy of fungal infections

  2005cited by this paper
• A Mechanism for Assembly of Complexes of Vitronectin and Plasminogen Activator Inhibitor-1 from Sedimentation Velocity Analysis*

  2005influential reference
• Metal ion/buffer interactions. Stability of binary and ternary complexes containing 2-[bis(2-hydroxyethyl)amino]-2(hydroxymethyl)-1,3-propanediol (Bistris) and adenosine 5'-triphosphate (ATP).

  2005cited by this paper
• Vitronectin: back into the spotlight

  2005cited by this paper
• Downloaded from jdr.sagepub.com at PENNSYLVANIA STATE UNIV on February 23, 2013 For personal use only. No other uses without permission. International and American Associations for Dental ResearchCRITICAL REVIEWS IN ORAL BIOLOGY & MEDICINE The Host Cytoki

  2005cited by this paper
• Clinical trials referral resource. Current clinical trials of cilengitide, an alpha(v) antagonist in clinical development as an anticancer agent.

  2004cited by this paper
• Genetic analysis of innate immunity in resistance to Candida albicans

  2004cited by this paper
• Disulfide bonding arrangements in active forms of the somatomedin B domain of human vitronectin.

  2004cited by this paper
• Hypofibrinolysis in the insulin resistance syndrome: implication in cardiovascular diseases

  2004cited by this paper
• Balance between matrix synthesis and degradation: a determinant of glomerulosclerosis

  2004cited by this paper
• Promotion of Leukocyte Adhesion by a Novel Interaction Between Vitronectin and the β2 Integrin Mac-1 (αMβ2, CD11b/CD18)

  2004cited by this paper
• CNTO 95, a fully human monoclonal antibody that inhibits αv integrins, has antitumor and antiangiogenic activity in vivo

  2004cited by this paper
• The Solution Structure of the N-terminal Domain of Human Vitronectin

  2004cited by this paper
• Calculating sedimentation coefficient distributions by direct modeling of sedimentation velocity concentration profiles.

  2004influential reference
• Canonical Inhibitor-like Interactions Explain Reactivity of α1-Proteinase Inhibitor Pittsburgh and Antithrombin with Proteinases*

  2003influential reference
• Selective extraction and characterization of a histidine-phosphorylated peptide using immobilized copper(II) ion affinity chromatography and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.

  2003cited by this paper
• Plasminogen activator inhibitor‐1, inflammation, obesity, insulin resistance and vascular risk

  2003cited by this paper
• Mutation of the highly conserved tryptophan in the serpin breach region alters the inhibitory mechanism of plasminogen activator inhibitor-1.

  2003influential reference
• A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis.

  2003cited by this paper
• Virulence factors of Candida species.

  2003cited by this paper
• Spectropotentiometric analysis of metal binding to structural zinc-binding sites: accounting quantitatively for pH and metal ion buffering effects.

  2003cited by this paper
• Candida albicans Septin Mutants Are Defective for Invasive Growth and Virulence

  2003cited by this paper
• How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration

  2003influential reference
• Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis.

  2003cited by this paper
• Biochemical importance of glycosylation of plasminogen activator inhibitor-1

  2003cited by this paper
• The 1.9-Å crystal structure of the noncollagenous (NC1) domain of human placenta collagen IV shows stabilization via a novel type of covalent Met-Lys cross-link

  2002cited by this paper
• Plasminogen activator inhibitor 1: physiological and pathophysiological roles.

  2002influential reference
• Myeloperoxidase Functions as a Major Enzymatic Catalyst for Initiation of Lipid Peroxidation at Sites of Inflammation*

  2002cited by this paper
• Kinetic Analysis of the Interaction between Vitronectin and the Urokinase Receptor*

  2002cited by this paper
• Incorporation of Vitronectin into Fibrin Clots

  2002cited by this paper
• Incorporation of vitronectin into fibrin clots. Evidence for a binding interaction between vitronectin and gamma A/gamma' fibrinogen.

  2002influential reference
• Plasminogen Activator Inhibitor Type 1 Promotes the Self-association of Vitronectin into Complexes Exhibiting Altered Incorporation into the Extracellular Matrix*

  2002influential reference
• The PKA phosphorylation of vitronectin: effect on conformation and function.

  2002cited by this paper
• The pathophysiology and treatment of Candida sepsis

  2002cited by this paper
• Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin.

  2002influential reference
• The pro‐ or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent

  2002cited by this paper
• X-Ray crystal structural determination of copper(II)-nitrilotriacetic acid-bis(N-methylimidazol-2-yl)ketone ternary complex

  2001cited by this paper
• Plasminogen Activator Inhibitor-1 Regulates Tumor Growth and Angiogenesis*

  2001influential reference
• The Serpins: Nature's Molecular Mousetraps

  2001cited by this paper
• Distinct ligand-binding modes for integrin alpha(v)beta(3)-mediated adhesion to fibronectin versus vitronectin.

  2001influential reference
• Inhibition of Angiogenesis in Vivo by Plasminogen Activator Inhibitor-1*

  2001influential reference
• Importance of the amino-acid composition of the shutter region of plasminogen activator inhibitor-1 for its transitions to latent and substrate forms.

  2001cited by this paper
• Model for the three‐dimensional structure of vitronectin: Predictions for the multi‐domain protein from threading and docking

  2001influential reference
• Prion Protein Binds Copper within the Physiological Concentration Range*

  2001cited by this paper
• Structural analysis of the interaction between urokinase-type plasminogen activator and its receptor: a potential target for anti-invasive cancer therapy.

  2001cited by this paper
• A method for defining binding sites involved in protein-protein interactions: analysis of the binding of plasminogen activator inhibitor 1 to the somatomedin domain of vitronectin.

  2001cited by this paper
• The CK2 phosphorylation of vitronectin. Promotion of cell adhesion via the alpha(v)beta 3-phosphatidylinositol 3-kinase pathway.

  2001cited by this paper
• Polymerization of Plasminogen Activator Inhibitor-1*

  2001influential reference
• Vitronectin Functions as a Cofactor for Rapid Inhibition of Activated Protein C by Plasminogen Activator Inhibitor-1

  2001influential reference
• Plasminogen Activator Inhibitor-1 and Its Cofactor Vitronectin Stabilize Arterial Thrombi After Vascular Injury in Mice

  2001cited by this paper
• Involvement of alpha(v)beta3 integrin-like receptor and glycosaminoglycans in Candida albicans germ tube adhesion to vitronectin and to a human endothelial cell line.

  2001cited by this paper
• Involvement of αvβ3 integrin-like receptor and glycosaminoglycans in Candida albicans germ tube adhesion to vitronectin and to a human endothelial cell line

  2001cited by this paper
• Thiolutin, an inhibitor of HUVEC adhesion to vitronectin, reduces paxillin in HUVECs and suppresses tumor cell‐induced angiogenesis

  2001influential reference
• Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology.

  2000cited by this paper
• PAI‐1 stability: the role of histidine residues

  2000cited by this paper
• Type 1 Plasminogen Activator Inhibitor Binds to Fibrin via Vitronectin*

  2000cited by this paper
• Epitope mapping of monoclonal antibodies directed to PAI-1 using PAI-1/PAI-2 chimera and PAI-1-derived synthetic peptides.

  2000cited by this paper
• Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice.

  2000cited by this paper
• Differential host susceptibility to pulmonary infections with bacteria and fungi in mice deficient in myeloperoxidase.

  2000influential reference
• Structures of active and latent PAI-1: a possible stabilizing role for chloride ions.

  2000influential reference
• Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling.

  2000influential reference
• New Insights into the Size and Stoichiometry of the Plasminogen Activator Inhibitor Type-1·Vitronectin Complex*

  2000influential reference
• Structure of a serpin–protease complex shows inhibition by deformation

  2000cited by this paper
• Vitronectin deficiency is associated with increased wound fibrinolysis and decreased microvascular angiogenesis in mice.

  2000influential reference
• Colocalization of thrombin, PAI-1, and vitronectin in the atherosclerotic vessel wall: A potential regulatory mechanism of thrombin activity by PAI-1/vitronectin complexes.

  2000cited by this paper
• Plasminogen-activator inhibitor type 1 and coronary artery disease.

  2000influential reference
• Dendritic Cells Discriminate between Yeasts and Hyphae of the Fungus Candida albicans

  2000cited by this paper
• Regulation of Angiogenesis in Vivo by Ligation of Integrin α5β1 with the Central Cell-Binding Domain of Fibronectin

  2000cited by this paper
• Innate and adaptive immunity in Candida albicans infections and saprophytism

  2000cited by this paper
• Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1.

  2000cited by this paper
• Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin.

  2000influential reference
• Hypofibrinolysis and increased PAI-1 are linked to atherothrombosis via insulin resistance and obesity.

  2000cited by this paper
• Severe Impairment in Early Host Defense againstCandida albicans in Mice Deficient in Myeloperoxidase

  1999influential reference
• Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans.

  1999cited by this paper
• Increased susceptibility of TNF-alpha lymphotoxin-alpha double knockout mice to systemic candidiasis through impaired recruitment of neutrophils and phagocytosis of Candida albicans.

  1999cited by this paper
• The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion.

  1999influential reference

• New Insights Into An Old Interaction: Developing A Model For PAI-1:VN Interactions

  2016cites this paper
• Investigating the Metal Binding Properties of Plasminogen Activator Inhibitor Type 1 (PAI-1) with Intrinsic Tryptophan Fluorescence

  2013cites this paper